| Companies sponsors |
Boehringer Ingelheim Ltd (spesolimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Changing Faces |
| |
Gene People |
| |
Genetic Alliance UK |
| |
Psoriasis and Psoriatic Arthritis Alliance |
| |
Psoriasis Association |
| |
Psoriasis Help Organisation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| Professional groups |
Association of Genetic Nurses & Counsellors |
| |
British Association of Dermatologists |
| |
British Dermatological Nursing Group |
| |
British Geriatrics Society |
| |
British Society for Cutaneous Allergy |
| |
British Society for Genetic Medicine |
| |
Primary Care Dermatology Society |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
St John’s Institute of Dermatology |
| |
UK Clinical Pharmacy Association |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
AbbVie (adalimumab, risankizumab) |
| |
Accord Healthcare (methotrexate) |
| |
Advanz Pharma (methotrexate) |
| |
Almirall (dimethyl fumarate, tildrakizumab) |
| |
Amgen (adalimumab, apremilast) |
| |
Aspire Pharma (dimethyl fumarate) |
| |
Biogen Idec (adalimumab, dimethyl fumarate, etanercept, infliximab) |
| |
Bristol Myers Squibb (deucravacitinib) |
| |
B&S Colorama (ciclosporin) |
| |
Celltrion Healthcare UK (adalimumab, infliximab) |
| |
Celix Pharma (dimethyl fumarate) |
| |
Dexcel-Pharma (ciclosporin) |
| |
Eli Lilly and Company (ixekizumab) |
| |
Fresenius Kabi (adalimumab) |
| |
Genus Pharmaceuticals (acitretin, dimethyl fumarate) |
| |
Hospira UK (methotrexate) |
| |
Johnson & Johnson Innovative Medicine (guselkumab, ustekinumab) |
| |
Leo Pharma (brodalumab) |
| |
Medac GmbH (methotrexate) |
| |
Merck Sharp & Dohme (infliximab) |
| |
Morningside Healthcare (acitretin, ciclosporin, methotrexate) |
| |
Mylan (ciclosporin, dimethyl fumarate) |
| |
Nordic Pharma (methotrexate) |
| |
Novartis Pharmaceuticals UK (ciclosporin, secukinumab) |
| |
Orion Pharma (UK) (methotrexate) |
| |
Pfizer (etanercept, infliximab, methotrexate) |
| |
Rosemont Pharmaceuticals (methotrexate) |
| |
Sandoz (adalimumab, etanercept, infliximab, methotrexate) |
| |
Santen UK (ciclosporin) |
| |
Teva UK (acitretin, ciclosporin, methotrexate) |
| |
Therakind Limited (methotrexate) |
| |
UCB Pharma (bimekizumab, certolizumab pegol) |
| |
Viatris (ciclosporin) |
| |
Wockhardt (dimethyl fumarate) |
| |
Zentiva (dimethyl fumarate) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
British Skin Foundation |
| |
Centre of Evidence-based Dermatology, University of Nottingham |
| |
Cochrane Skin Group |
| |
Dermatrust |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |